Ibrutinib and

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Analysis of factors influencing SARS-CoV-2 infection and outcomes in patients with chronic lymphocytic leukemia during the burst of COVID-19 epidemic.BMC cancer · 2026
   Article
2. Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study.Annals of intensive care · 2023
   Article
3. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.International journal of molecular sciences · 2023
   Review
4. Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.Cancers · 2021
   Article
5. The robust and rapid role of molecular testing in precision fungal diagnostics: A case report.Medical mycology case reports · 2020
   Article
6. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature.Medical mycology case reports · 2020
   Article
7. A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.Medical mycology case reports · 2020
   Article
8. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.Blood · 2019
   Review
9. Bruton Tyrosine Kinase Inhibitors: Present and Future.Cancer journal (Sudbury, Mass.)
   Review

Corrections and comments

• Comment on
  Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as